Literature DB >> 18166410

The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002.

Anna S Kitzmann1, Jose S Pulido, Nancy N Diehl, David O Hodge, James P Burke.   

Abstract

PURPOSE: To determine the incidence of central serous chorioretinopathy (CSC) in Olmsted County, Minnesota from 1980 to 2002, determine the associated risk factors for CSC based on previously reported risk factors, investigate for any new risk factors not previously reported, and determine a population-based recurrence rate.
DESIGN: Population-based retrospective cohort and case-control study. PARTICIPANTS: Cases were all patients with newly diagnosed CSC in Olmsted County Minnesota, from January 1, 1980 through December 31, 2002. Controls were selected from the same general population. Control group 1 patients were matched for age, gender, length of medical follow-up, and index date (corresponding with date of diagnosis for cases). Control group 2 patients were matched for all the same criteria as control group 1, and they had documented normal eye examination results.
METHODS: Using the Rochester Epidemiology Project medical records linkage system, which captures virtually all medical care provided to residents of Olmsted County, Minnesota, we identified all cases of CSC in county residents between 1980 and 2002. We reviewed the entire medical record of cases and applied standardized criteria for CSC. The medical records of cases and controls were reviewed for the presence of risk factors as well. MAIN OUTCOME MEASURE: Incidence of CSC. Secondary outcomes were also evaluated.
RESULTS: There were 74 cases (63 men, 11 women) of CSC. Mean annual age-adjusted incidences per 100 000 were 9.9 (95% confidence interval [CI], 7.4-12.4) for men and 1.7 (95% CI, 0.7-2.7) for women. The incidence of CSC was approximately 6 times higher in men than in women (P<0.001). There were no significant risk factors identified for CSC. Twenty-three (31%) of the 74 patients with CSC had recurrences. The mean number of recurrences was 1.5 (range, 1-4). Median time from diagnosis to recurrence was 1.3 years (range, 0.4-18.2).
CONCLUSION: The incidence of CSC has not previously been reported in a population-based study. In accordance with previous studies, we found that CSC occurs more frequently in men than in women.

Entities:  

Mesh:

Year:  2008        PMID: 18166410     DOI: 10.1016/j.ophtha.2007.02.032

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  108 in total

1.  Response of central serous chorioretinopathy evaluated by multimodal retinal imaging.

Authors:  R Sacconi; G Baldin; A Carnevali; L Querques; A Rabiolo; G Marchini; F Bandello; G Querques
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

2.  Choroidal thickness in relation to sex, age, refractive error, and axial length in healthy Turkish subjects.

Authors:  Ibrahim Tuncer; Eyyup Karahan; Mehmet Ozgur Zengin; Eray Atalay; Nihat Polat
Journal:  Int Ophthalmol       Date:  2014-06-21       Impact factor: 2.031

3.  Finasteride is effective for the treatment of central serous chorioretinopathy.

Authors:  E Moisseiev; A J Holmes; A Moshiri; L S Morse
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

4.  A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy.

Authors:  Lijun Zhou; Victor Chong; Kunbei Lai; Chuangxin Huang; Fabao Xu; Yajun Gong; Maimaitiaili Youlidaxi; Tao Li; Lin Lu; Chenjin Jin
Journal:  Lasers Med Sci       Date:  2019-02-02       Impact factor: 3.161

5.  Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy.

Authors:  Meltem Guzin Altınel; Banu Acikalin; Hasan Gunes; Gokhan Demir
Journal:  Lasers Med Sci       Date:  2021-01-07       Impact factor: 3.161

Review 6.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

7.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

8.  En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy.

Authors:  Daniela Ferrara; Kathrin J Mohler; Nadia Waheed; Mehreen Adhi; Jonathan J Liu; Ireneusz Grulkowski; Martin F Kraus; Caroline Baumal; Joachim Hornegger; James G Fujimoto; Jay S Duker
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

9.  Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study.

Authors:  Rosa L Schellevis; Elon H C van Dijk; Myrte B Breukink; Lebriz Altay; Bjorn Bakker; Bobby P C Koeleman; Lambertus A Kiemeney; Dorine W Swinkels; Jan E E Keunen; Sascha Fauser; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon; Eiko K de Jong
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

10.  Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy.

Authors:  Olesya Zavoloka; Pavlo Bezditko; Irina Lahorzhevska; Darya Zubkova; Yevgeniya Ilyina
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-03-16       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.